Metformin Inhibits the Development of l-DOPA-Induced Dyskinesia in a Murine Model of Parkinson’s Disease

Metformin protects the brain against ischemia/reperfusion injury through PI3K/Akt1/JNK3 signaling pathways in rats

(2017) Xu-Hua Ge et al.   PHYSIOLOGY & BEHAVIOR

Gadd45β ameliorates L-DOPA-induced dyskinesia in a Parkinson's disease mouse model

(2016) Hye-Yeon Park et al.   NEUROBIOLOGY OF DISEASE

Inhibition of Glycogen Synthase Kinase-3β (GSK-3β) as potent therapeutic strategy to ameliorates L-dopa-induced dyskinesia in 6-OHDA parkinsonian rats

(2016) Cheng-long Xie et al.   Scientific Reports

Metformin and gefitinib cooperate to inhibit bladder cancer growth via both AMPK and EGFR pathways joining at Akt and Erk

(2016) Mei Peng et al.   Scientific Reports

New treatments for levodopa-induced motor complications

(2015) Olivier Rascol et al.   MOVEMENT DISORDERS

Amantadine extended release for levodopa-induced dyskinesia in Parkinson's disease (EASED Study)

(2015) Rajesh Pahwa et al.   MOVEMENT DISORDERS

M4 Muscarinic Receptor Signaling Ameliorates Striatal Plasticity Deficits in Models of L-DOPA-Induced Dyskinesia

(2015) Weixing Shen et al.   NEURON

Glycogen synthase kinase-3 beta (GSK-3β) signaling: Implications for Parkinson's disease

(2015) Mojtaba Golpich et al.   PHARMACOLOGICAL RESEARCH

Ribosomal Protein S6 Phosphorylation in the Nervous System: From Regulation to Function

(2015) Anne Biever et al.   Frontiers in Molecular Neuroscience

Metformin Treatment in the Period After Stroke Prevents Nitrative Stress and Restores Angiogenic Signaling in the Brain in Diabetes

(2014) Mohammed Abdelsaid et al.   DIABETES

Inhibition of Adenylyl Cyclase Type 5 Prevents L-DOPA-Induced Dyskinesia in an Animal Model of Parkinson's Disease

(2014) H.-Y. Park et al.   JOURNAL OF NEUROSCIENCE

Metformin—mode of action and clinical implications for diabetes and cancer

(2014) Ida Pernicova et al.   Nature Reviews Endocrinology

Neuroprotective effect of metformin in MPTP-induced Parkinson’s disease in mice

(2014) S.P. Patil et al.   NEUROSCIENCE

Use of metabotropic glutamate 5-receptor antagonists for treatment of levodopa-induced dyskinesias

(2014) Olivier Rascol et al.   PARKINSONISM & RELATED DISORDERS

Quantification of metformin by the HPLC method in brain regions, cerebrospinal fluid and plasma of rats treated with lipopolysaccharide

(2014) Krzysztof Łabuzek et al.   Pharmacological Reports

Cell type-specific plasticity of striatal projection neurons in parkinsonism and L-DOPA-induced dyskinesia

(2014) Tim Fieblinger et al.   Nature Communications

Serotonin System Implication in l-DOPA-Induced Dyskinesia: From Animal Models to Clinical Investigations

(2014) Manolo Carta et al.   Frontiers in Neurology

The protective role of AMP-activated protein kinase in alpha-synuclein neurotoxicity in vitro

(2013) Marija Dulovic et al.   NEUROBIOLOGY OF DISEASE

Withdrawing amantadine in dyskinetic patients with Parkinson disease: The AMANDYSK trial

(2013) F. Ory-Magne et al.   NEUROLOGY

Haloperidol promotes mTORC1-dependent phosphorylation of ribosomal protein S6 via dopamine- and cAMP-regulated phosphoprotein of 32 kDa and inhibition of protein phosphatase-1

(2013) Alessandra Bonito-Oliva et al.   NEUROPHARMACOLOGY

Activity-dependent regulation of dendritic growth and maintenance by glycogen synthase kinase 3β

(2013) Yanfang Rui et al.   Nature Communications

Metformin improves healthspan and lifespan in mice

(2013) Alejandro Martin-Montalvo et al.   Nature Communications

Targeting Glutamate Receptors to Tackle the Pathogenesis, Clinical Symptoms and Levodopa-Induced Dyskinesia Associated with Parkinson’s Disease

(2012) Susan Duty   CNS DRUGS

AMP Kinase Activation Mitigates Dopaminergic Dysfunction and Mitochondrial Abnormalities in Drosophila Models of Parkinson's Disease

(2012) C.-H. Ng et al.   JOURNAL OF NEUROSCIENCE

Effects of metformin on learning and memory behaviors and brain mitochondrial functions in high fat diet induced insulin resistant rats

(2012) Hiranya Pintana et al.   LIFE SCIENCES

Metformin-inclusive sulfonylurea therapy reduces the risk of Parkinson's disease occurring with Type 2 diabetes in a Taiwanese population cohort

(2012) Mark L. Wahlqvist et al.   PARKINSONISM & RELATED DISORDERS

Deletion of GSK3  in D2R-expressing neurons reveals distinct roles for  -arrestin signaling in antipsychotic and lithium action

(2012) N. M. Urs et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Amantadine attenuates levodopa-induced dyskinesia in mice and rats preventing the accompanying rise in nigral GABA levels

(2011) Simone Bido et al.   JOURNAL OF NEUROCHEMISTRY

SNCA,MAPT, andGSK3Bin Parkinson disease: a gene-gene interaction study

(2010) C. Wider et al.   EUROPEAN JOURNAL OF NEUROLOGY

Involvment of Cytosolic and Mitochondrial GSK-3β in Mitochondrial Dysfunction and Neuronal Cell Death of MPTP/MPP+-Treated Neurons

(2009) Agnès Petit-Paitel et al.   PLoS One

Inhibition of mTOR Signaling in Parkinson's Disease Prevents L-DOPA-Induced Dyskinesia

(2009) E. Santini et al.   Science Signaling

Akt/GSK3 Signaling in the Action of Psychotropic Drugs

(2008) Jean-Martin Beaulieu et al.   Annual Review of Pharmacology and Toxicology

The role of GSK-3 in synaptic plasticity

(2008) S Peineau et al.   BRITISH JOURNAL OF PHARMACOLOGY

l-DOPA activates ERK signaling and phosphorylates histone H3 in the striatonigral medium spiny neurons of hemiparkinsonian mice

(2008) Emanuela Santini et al.   JOURNAL OF NEUROCHEMISTRY

Molecular mechanisms of L-DOPA-induced dyskinesia

(2008) Peter Jenner   NATURE REVIEWS NEUROSCIENCE

Glycogen synthase kinase-3beta is associated with Parkinson's disease

(2008) Masahiro Nagao et al.   NEUROSCIENCE LETTERS